Recent advances in immunotherapy for non-small-cell lung cancer.

Abstract

Despite of recent development in the field of molecular targeted therapies, lung cancer is a leading cause of cancer death in the world. Remarkable progress has been made recently in immunotherapy for patients with non-small-cell lung cancer (NSCLC), with several modalities, concepts, and treatment settings being investigated. In vaccine development, large-scale clinical trials such as those with L-BLP25, belagenpumatucel-L, TG4010, and talactoferrin are already ongoing and some results have been reported. A trial of a vaccine as adjuvant therapy for patients with completely resected NSCLC is also ongoing with one of the major cancer-testis antigens, melanoma-associated antigen (MAGE)-A3. More recently, the effectiveness of multiple peptide vaccines has also been shown. Recently developed unique treatment modalities are the immune checkpoint inhibitors, such as antibodies against PD-1 and PD-L1, which also show promise. However, although therapeutic cancer vaccines are generally thought to be safe, severe adverse events should be monitored carefully when using immune checkpoint inhibitors. Here, we discuss recent advances and future perspectives of immunotherapy for patients with NSCLC.

• Authors: Hiroyuki Suzuki, Yuki Owada, Yuzuru Watanabe, Takuya Inoue, Mitsuro Fukuharav, Takumi Yamaura, Satoshi Mutoh, Naoyuki Okabe, Hiroshi Yaginuma, Takeo Hasegawa, Atsushi Yonechi, Jun Ohsugi, Mika Hoshino, Mitsunori Higuchi, Yutaka Shio, Mitsukazu Gotoh
• Journal: Human vaccines & immunotherapeutics (Hum Vaccin Immunother) Vol. 10 Issue 2 Pg. 352-7 ( 2014) ISSN: 2164-554X [Electronic] United States
• PMID: 24196313 (Publication Type: Journal Article, Review)

Chemical References

• Cancer Vaccines

Topics

• Cancer Vaccines (administration & dosage)
• Carcinoma, Non-Small-Cell Lung (therapy)
• Clinical Trials as Topic
• Humans
• Immunotherapy (methods, trends)
• Treatment Outcome